Stock APLLTD ALEMBIC PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alembic Pharmaceuticals Limited

Equities

APLLTD

INE901L01018

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:51 2024-05-31 am EDT 		5-day change 1st Jan Change
923.1 INR -2.05% Intraday chart for Alembic Pharmaceuticals Limited -2.83% +21.56%
May. 30 Alembic Pharmaceuticals Gets US FDA Final Nod for Sacubitril and Valsartan Tablets MT
May. 09 Transcript : Alembic Pharmaceuticals Limited, Q4 2024 Earnings Call, May 09, 2024

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 101,386 100,715 189,674 145,771 97,564 181,447 - -
Enterprise Value (EV) 1 108,614 117,382 190,614 152,248 103,100 193,575 180,612 178,147
P/E ratio 17.3 x 12.1 x 15.9 x 26.7 x 28.5 x 31.4 x 25.9 x 20.7 x
Yield 1.02% 1.31% 1.45% 1.35% 1.61% 0.96% 0.95% 1.2%
Capitalization / Revenue 2.58 x 2.19 x 3.52 x 2.75 x 1.73 x 3.11 x 2.6 x 2.33 x
EV / Revenue 2.76 x 2.55 x 3.53 x 2.87 x 1.82 x 3.11 x 2.59 x 2.29 x
EV / EBITDA 12.4 x 9.6 x 12.2 x 17.4 x 14.6 x 20.7 x 15.7 x 12.8 x
EV / FCF 68.7 x -52.5 x 23.7 x 120 x 36.8 x 40.7 x 41.6 x 27.9 x
FCF Yield 1.45% -1.9% 4.22% 0.83% 2.72% 2.46% 2.4% 3.58%
Price to Book 3.73 x 3.13 x 3.7 x 2.79 x 2.23 x 3.82 x 3.39 x 3.04 x
Nbr of stocks (in thousands) 188,520 188,516 196,563 196,563 196,563 196,563 - -
Reference price 2 537.8 534.2 965.0 741.6 496.4 923.1 923.1 923.1
Announcement Date 5/8/19 4/23/20 5/4/21 5/2/22 5/5/23 5/9/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 39,347 46,058 53,931 53,058 56,526 62,286 69,850 77,846
EBITDA 1 8,736 12,230 15,576 8,742 7,084 9,334 11,515 13,945
EBIT 1 7,584 10,657 13,741 5,874 4,329 6,607 8,571 10,639
Operating Margin 19.27% 23.14% 25.48% 11.07% 7.66% 10.61% 12.27% 13.67%
Earnings before Tax (EBT) 1 7,493 9,998 13,681 6,201 3,855 6,328 8,386 10,567
Net income 1 5,844 8,291 11,781 5,457 3,420 6,158 6,978 8,686
Net margin 14.85% 18% 21.84% 10.28% 6.05% 9.89% 9.99% 11.16%
EPS 2 31.00 43.98 60.81 27.76 17.40 31.33 35.63 44.59
Free Cash Flow 1 1,580 -2,235 8,039 1,267 2,805 4,757 4,343 6,384
FCF margin 4.02% -4.85% 14.91% 2.39% 4.96% 7.64% 6.22% 8.2%
FCF Conversion (EBITDA) 18.09% - 51.61% 14.5% 39.6% 50.97% 37.72% 45.78%
FCF Conversion (Net income) 27.04% - 68.23% 23.22% 82.03% 77.25% 62.24% 73.5%
Dividend per Share 2 5.500 7.000 14.00 10.00 8.000 8.874 8.733 11.12
Announcement Date 5/8/19 4/23/20 5/4/21 5/2/22 5/5/23 5/9/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 13,143 12,804 13,260 12,923 12,717 14,157 12,621 14,750 15,090 14,064 14,862 15,448 16,275 16,060 15,991
EBITDA 1 3,651 3,417 2,359 2,572 2,557 1,601 146.5 2,327 2,488 2,122 1,987 2,452 2,444 2,606 2,694
EBIT 3,181 - - - 1,997 370.2 - 1,650 1,822 1,381 - - 1,536 1,706 1,925
Operating Margin 24.2% - - - 15.7% 2.61% - 11.19% 12.08% 9.82% - - 9.44% 10.62% 12.04%
Earnings before Tax (EBT) 1 3,183 2,919 1,826 2,002 1,967 405.9 -601.6 1,530 1,681 1,246 1,298 1,587 1,680 1,695 1,925
Net income 1 2,926 2,507 1,645 1,693 1,764 354.6 -658.8 1,334 1,219 1,526 1,206 1,470 1,413 1,467 1,598
Net margin 22.26% 19.58% 12.41% 13.1% 13.87% 2.5% -5.22% 9.04% 8.08% 10.85% 8.11% 9.51% 8.68% 9.14% 9.99%
EPS 14.88 12.75 8.370 8.610 8.980 1.800 - 6.780 6.200 - - - 5.250 6.000 8.100
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 1/19/21 5/4/21 7/26/21 11/10/21 2/10/22 5/2/22 8/4/22 11/11/22 2/1/23 5/5/23 8/4/23 - - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 7,228 16,667 941 6,477 5,536 2,617 - -
Net Cash position 1 - - - - - - 836 3,301
Leverage (Debt/EBITDA) 0.8274 x 1.363 x 0.0604 x 0.7409 x 0.7815 x 0.28 x - -
Free Cash Flow 1 1,580 -2,235 8,039 1,267 2,805 4,757 4,343 6,384
ROE (net income / shareholders' equity) 23.7% 27.9% 28.2% 10.5% 7.12% 12.8% 13.8% 15.5%
ROA (Net income/ Total Assets) - - 18.6% 7.89% 5.14% - - -
Assets 1 - - 63,489 69,152 66,525 - - -
Book Value Per Share 2 144.0 171.0 261.0 266.0 222.0 241.0 272.0 304.0
Cash Flow per Share 2 43.10 23.80 75.50 27.60 36.80 42.80 49.20 43.10
Capex 1 6,539 6,726 6,595 4,256 4,434 3,275 2,889 3,092
Capex / Sales 16.62% 14.6% 12.23% 8.02% 7.84% 5.26% 4.14% 3.97%
Announcement Date 5/8/19 4/23/20 5/4/21 5/2/22 5/5/23 5/9/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Alembic Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
923.1 INR
Average target price
980.3 INR
Spread / Average Target
+6.20%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ALEMBIC PHARMACEUTICALS LIMITED Stock Alembic Pharmaceuticals Limited
+21.56% 2.17B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. APLLTD Stock
  4. Financials Alembic Pharmaceuticals Limited